| 摘要 |
Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-&bgr;1) are provided, particularly recognizing human and mouse TGF-&bgr;1 and not recognizing or binding TGF-&bgr;2 or TGF-&bgr;3. Particular antibodies are provided which specifically recognize and neutralize TGF-&bgr;1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-&bgr;1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-&bgr;1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein. |
